OvaGene Licenses miRNA Technology from Moffitt for Drug Response Assays | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OvaGene Oncology has completed a licensing and collaboration agreement with the Moffitt Cancer Center to develop and commercialize proprietary microRNA assays to predict drug response for currently used cancer drugs, the Irvine, Calif.-based molecular diagnostics firm announced on Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.